News
-
-
-
-
-
PRESS RELEASE
SAF-HOLLAND sets new medium-term targets with the 'drive2030' corporate strategy – Group sales expected to increase by more than 50% to over EUR 3,000 million
SAF-HOLLAND presents 'drive2030' strategy at Capital Markets Day, targeting over €3bn in sales & 10-12% EBIT margin by 2030. Focus on growth, efficiency, and sustainability -
-
PRESS RELEASE
2024 Annual Results: Strong Growth and Exceptional Improvement Across All Profitability Indicators
STIF (FR001400MDW2, ALSTI) reports strong growth and exceptional improvement in all profitability indicators in 2024. Revenue up by 72.7% driven by BESS activity. Plans for further growth, product diversification, and geographical expansion in 2025 -
-
PRESS RELEASE
Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine ? Strong Outlook for 2025
Transgene achieves key milestones in 2024, including clinical proof of principle for individualized cancer vaccine TG4050, with strong outlook for 2025. New trial planned in Q4 2025 for a second indication -